Balanced news tone
News Sentiment
NUVL sentiment intelligence
Nuvalent Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +0.4% over four weeks, trend active, and materially above fair value.
Deerfield holders cash out of Nuvalent (NUVL) at $124 per share
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Nuvalent (NUVL) CFO sells 11,430 shares and exercises options under plan
Nuvalent, Inc.'s CFO, Alexandra Balcom, exercised stock options for 11,430 shares and subsequently sold the same number of shares (11,430) at a weighted average price of $123.58 per share. These transactions were executed on July 1, 2026, under a Rule 10b5-1 trading plan adopted
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 20:12
- Source
- Stock Titan
Nuvalent (NUVL) CDO exercises options and sells 23,000 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options for 23,000 shares of Class A Common Stock on July 1, 2026, at exercise prices of $72.35 and $18.93 per share. Immediately after, she sold all 23,000 shares in an open-market transaction at a weighted aver
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 20:12
- Source
- Stock Titan
NUVL (NASDAQ: NUVL) Form 144 lists insider sale of Class A Common
Nuvalent, Inc. (NUVL) has filed a Form 144 with the SEC, indicating a proposed insider sale of Class A Common shares via NQ Stock Options, with J.P. Morgan Securities LLC named as the broker. The filing also details multiple past sales attributed to Alexandra Balcom, occurring be
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
Insider at Nuvalent (NUVL) exercises options and sells 5,500 shares
Nuvalent's Chief Development Officer, Darlene Noci, exercised stock options to acquire 5,500 shares at $27.85 per share and subsequently sold those 5,500 shares in the open market for a weighted average price of $123.51 per share. These transactions were conducted under a pre-arr
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 20:10
- Source
- Stock Titan
GSK plc (GSK) Launches Tender Offer to Acquire Nuvalent Inc. for $124 Per Share
GSK plc has launched a tender offer to acquire Nuvalent, Inc. for $124 per share in cash, following a merger agreement signed on June 9, 2026. This move represents a significant step in GSK's strategic acquisitions. Additionally, GSK's ViiV Healthcare has introduced the PrEP Wisd
- Tone
- Positive 71/100
- Event
- Deals and strategy
- Published
- 30 Jun 2026 13:40
- Source
- Insider Monkey
Enterprise value to revenue forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, specifically its enterprise value to revenue (forward) metric. The content indicates that the market was closed and no trades were made for this stock. The data is provided by ICE Data Services and FactSet Re
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 17:40
- Source
- TradingView
Price to book forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange (FWB:5AX). It specifically highlights the "Price to book forward" metric. The content itself seems to be a placeholder or a snippet from a financial data platform, showi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 01:40
- Source
- TradingView
Nuvalent, Inc. Class A Actuals & Estimates (NASDAQ:NUVL)
This article provides an overview of Nuvalent, Inc. (NASDAQ: NUVL) stock's actuals and estimates, including its current stock price, historical performance, analyst forecasts, and various financial metrics. It details the company's market capitalization, earnings per share, reven
- Tone
- Positive 70/100
- Event
- Earnings
- Published
- 26 Jun 2026 01:39
- Source
- TradingView
Price to earnings forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A, traded on the Frankfurt Stock Exchange under the symbol FWB:5AX. It specifically highlights the "Price to earnings forward" metric for the company. The content appears to be a financial data page from Trading
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 17:39
- Source
- TradingView
Enterprise value to EBITDA forward of Nuvalent, Inc. Class A – FWB:5AX
This article provides financial information for Nuvalent, Inc. Class A (FWB:5AX), specifically its enterprise value to EBITDA forward. It notes that the market was closed with no trades. The data is made available through TradingView, sourcing information from ICE Data Services a
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 10:11
- Source
- TradingView
GSK Unit Launches Tender Offer for Nuvalent Acquisition
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 24 Jun 2026 16:02
- Source
- MT Newswires
Here’s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB)
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 16 Jun 2026 18:45
- Source
- Insider Monkey
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 16:25
- Source
- MarketBeat
A Look At Nuvalent (NUVL) Valuation After Strong Multi‑Year Share Price Gains
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- simplywall.st
Nuvalent, a Nasdaq-listed bio company in the U.S., hit an all-time high on the news of the acquisiti..
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 07:00
- Source
- 매일경제
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- CNBC
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Investor's Business Daily
GSK enters agreement to acquire Nuvalent, Inc.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- GSK US
GSK boosts cancer portfolio with $10.6 billion Nuvalent takeover
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Reuters
FTSE 100 down as GSK buys US drugmaker Nuvalent
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- marketscreener.com
Stocks making the biggest moves premarket: GSK, Nuvalent, J.M. Smucker, SailPoint and more
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- CNBC
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Market source
London's FTSE 100 falls as GSK slides after Nuvalent deal
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 09 Jun 2026 07:00
- Source
- TradingView
GSK’s $10.6B Nuvalent takeover fails to impress investors as shares fall: here's why
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- TradingView
Does Nuvalent (NUVL) Have the Pipeline Depth to Justify Its Global Expansion Ambitions?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- simplywall.st
Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- simplywall.st
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source